 Orgenesis Inc NASDAQ:ORGS FRA:45O has announced multiple milestones in the development of Ranpirnase for multiple indications, including anogenital warts, adenoviral conjunctivitis and even coronavirus COVID-19. First, Orgenesis has completed its pre-Investigational New Drug IND consultation with the US Food and Drug Administration FDA, discussing RanTop Ranpirnase topical gel for the treatment of anogenital warts AGW. 